Findings show long-term renal toxicity in a preclinical model using targeted alpha-radioimmunotherapy, suggesting potential optimization strategies.
This study shows that long-term toxicity is induced by [²¹²Pb]Pb-TCMC-rituximab, particularly affecting the kidneys. However, it highlights that this renal toxicity can be reduced through optimization, possibly by modifying the specific activity of the treatment.
No takes yet. Share an insight, caveat, or question.
Quelven et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: